Off the wire
Xinhua China news advisory -- June 3  • Garden festival kicks off in Ireland, attracts residents, visitors  • Venezuela sends aid to Cuba after tropical storm Alberto  • Venezuela prepares list of political opponents to be freed from jail  • JSE edges weaker as firmer South African rand pulls down mines  • JSE closes lower as U.S. dollar continues to gain  • JSE closes higher buoyed by banks and general retailers  • Microsoft eyes establishing software start-up in Turkey  • Chinese mainland claims 6 of world's top 100 universities in latest THE rankings  • U.S.-EU trade war could "devastate" Irish whiskey industry: IWA  
You are here:   News/

Chinese scientists produce genetically-enhanced human vascular cells

Xinhua,January 18, 2019 Adjust font size:

Chinese scientists produced the world's first genetically-engineered human blood vessel cells, providing a promising option for therapeutic use.

The study published on Thursday in the journal Cell Stem Cell showed that human vascular cell function can be enhanced by editing a single longevity-related gene.

Scientists from the Institute of Biophysics of the Chinese Academy of Sciences (CAS), Peking University and the Institute of Zoology of CAS targeted a gene called FOXO3, an important regulator to delay cellular aging, resist stresses and enhance cardiovascular balance.

Compared with those of wildtype cells, the genetically-enhanced vascular cells could efficiently promote vascular repair and regeneration, increasing resistance to oxygen-causing injury, according to the study.

The technique can also resist the cells' transformation into tumors. The risk of tumor transformation used to be a major concern for the application of the gene-editing technology.

The researchers tested it in a mouse model with blood-shortage or ischemic injury and found that those cells promoted vascular regeneration and resisted tumor transformation both in vitro and in vivo.

They expected to use gene-editing strategies in the future to produce high-quality, safe human vascular cell grafts in a large-scale and standardized manner.